Novartis’ remibrutinib shows promise for patients with CSU
Highly selective inhibitor therapy treats patients with chronic spontaneous urticaria
Read More
Tag: chronic spontaneous urticaria
US breakthrough designation for ligelizumab in chronic spontaneous urticaria
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair
Read More
Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
Read More
